RecruitingPHASE1, PHASE2NCT05187338
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Studying Sarcoma of cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Principal Investigator
- Zhenfeng Zhang, MD, PHDSecond Affiliated Hospital of Guangzhou Medical University
- Intervention
- ipilimumab +pembrolizumab +durvalumab(drug)
- Enrollment
- 100 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2021 – 2035
Study locations (1)
- The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05187338 on ClinicalTrials.govOther trials for Sarcoma of cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07071727Short Course of Radiotherapy Prior to Surgery of Soft Tissue SarcomasThe Netherlands Cancer Institute
- RECRUITINGPHASE2NCT07192068Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.UNICANCER
- RECRUITINGPHASE1NCT06771219SLV-154 Treatment of Metastatic Solid TumorsSolve Therapeutics
- RECRUITINGNCT06904365Ovarian-Sparing Adaptive Radiotherapy in Young Adult WomenWashington University School of Medicine
- RECRUITINGPHASE2NCT06580002Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot TrialUniversity of California, Irvine
- RECRUITINGNANCT06103669Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)University of California, Davis
- RECRUITINGNCT05366881cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseAdela, Inc
- RECRUITINGNANCT03017573Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)Institut Curie